Can Tirzepatide Spare More Muscle? Roche’s Emugrobart Trial Is About to Give Us a Clue
A 285-person phase 2 trial is testing tirzepatide with emugrobart, an anti-myostatin antibody. Here’s what it may reveal about fat loss, lean mass and the limits of the evidence.
The next fight in obesity medicine may not be about who loses the most weight. It may be about what that weight is made of.
Roche is testing a different kind of companion for tirzepatide: emugrobart, also known as RO7204239 or GYM329, an investigational antibody designed to block myostatin, one of the body’s natural brakes on muscle growth. The phase 2 GYMINDA study is active but no longer recruiting, and its estimated primary-completion date is August 22, 2026. That makes it one of the clearest near-term tests of a question patients already care about: can powerful medical weight loss become more selective for fat while protecting lean tissue?
There is no answer yet. GYMINDA has not posted efficacy results, and emugrobart is not approved for obesity. But the trial’s design, together with new human data from a related muscle-directed drug, shows where the field is heading.
The trial that quietly changed status
The ClinicalTrials.gov record for NCT06965413 lists 285 participants enrolled across a randomized, double-blind, placebo-controlled phase 2 study. The registry was updated on August 11 and now describes the study as active, not recruiting. Roche’s own trial page says adults with obesity, or overweight plus a weight-related condition, receive tirzepatide as background treatment and are randomized among four emugrobart or placebo arms.
The core treatment period lasts 48 weeks. It is followed by a 24-week extension in which tirzepatide is stopped, then a 24-week post-treatment follow-up. That extension is unusually interesting. It can help researchers look beyond the scale at what happens when the appetite-targeting component is withdrawn: whether body composition, weight or other measures diverge after tirzepatide ends.
The primary objective is straightforward: compare body-weight change after 48 weeks between emugrobart-plus-tirzepatide and placebo-plus-tirzepatide. The broader scientific value will depend on secondary outcomes, safety data and body-composition measurements. A larger muscle does not automatically mean a stronger or healthier muscle, so function matters alongside mass.
Why combine a myostatin blocker with tirzepatide?
Tirzepatide activates GIP and GLP-1 receptors. It reduces appetite and produces substantial weight loss, but weight loss is never pure fat loss. Lean tissue moves too. In a DXA substudy of SURMOUNT-1, 160 participants had scans at baseline and week 72. The pooled tirzepatide group lost 21.3% of body weight, while fat mass fell 33.9% and lean mass fell 10.9%. About 75% of the lost weight was fat and 25% was lean mass.
Those numbers come from a peer-reviewed 2025 analysis, not from the new Roche trial. They also need context. Lean mass on DXA includes more than contractile skeletal muscle, and some lean-tissue reduction is expected when a smaller body requires less tissue to support it. Still, the finding gives drug developers a target: preserve more useful tissue while retaining the metabolic benefits of fat loss.
Emugrobart approaches the problem from the other side. Myostatin is a signaling protein that limits skeletal-muscle growth. Roche describes emugrobart as a humanized monoclonal antibody that binds latent myostatin. In plain English, tirzepatide turns down energy intake while emugrobart tries to release a muscle-growth brake. The intended combination is not a bigger dose of the same idea. It is two mechanisms aimed at different parts of body composition.
The closest human proof does not use emugrobart
The most persuasive reason to watch GYMINDA comes from BELIEVE, a randomized phase 2 trial published in Nature Medicine in March 2026. BELIEVE tested semaglutide with bimagrumab, an investigational antibody that blocks type II activin receptors. Bimagrumab and emugrobart are not the same drug and do not bind the same target in precisely the same way. The trial is supporting evidence for the strategy, not a preview that can be copied onto Roche’s molecule.
BELIEVE randomized 507 adults with obesity across nine groups for 48 weeks, followed by an open-label extension to week 72. At week 48, least-squares mean weight change was minus 17.8 kilograms with high-dose bimagrumab plus semaglutide 2.4 mg, compared with minus 14.2 kilograms for semaglutide 2.4 mg, minus 9.3 kilograms for high-dose bimagrumab and minus 3.3 kilograms for placebo. All active comparisons cited in the abstract were statistically significant versus placebo.
The composition signal was more revealing than the extra kilograms. At week 48, total lean mass fell 2.6% with the high-dose combination, versus 7.9% with high-dose semaglutide alone. The study calculated that 92.3% of weight lost with the high-dose combination came from fat, compared with 71.1% on semaglutide 2.4 mg. These are trial-level averages, not guarantees for an individual, but they support the idea that a muscle-directed companion can change the quality of pharmacologic weight loss.
What the early excitement can miss
First, preserved lean mass is not identical to preserved strength. A therapy could increase measured tissue without delivering proportional improvements in mobility, power or long-term independence. The most convincing future program would pair DXA or MRI with functional endpoints such as strength, gait, exercise capacity and patient-reported physical function.
Second, muscle-directed antibodies bring their own adverse effects. In BELIEVE, common events associated with bimagrumab included muscle spasms, diarrhea and acne. Semaglutide was associated with nausea, diarrhea, constipation and fatigue. The active-treatment groups had high overall adverse-event rates, and discontinuations varied by regimen. GYMINDA must establish emugrobart’s own safety profile rather than borrowing reassurance from a different antibody.
Third, the trial population matters. Roche excludes diabetes from GYMINDA and excludes several conditions that could confound muscle measurements or increase risk. Results from a controlled group of adults with obesity or overweight cannot automatically be generalized to frail older adults, people with sarcopenia, patients recovering from illness or anyone using unsupervised compounded products.
Finally, the primary-completion date is not a results date. Database cleaning, analysis, conference scheduling and peer review can add months. An August milestone means the core data collection is nearing its planned endpoint; it does not mean a validated treatment decision arrives the next morning.
What to watch when results arrive
The headline will probably be total weight change, but the more useful questions sit underneath it:
How much fat mass and lean mass changed in each arm, measured with a validated imaging method.
Whether emugrobart improved strength or function, not just tissue volume.
Whether added fat loss came with a tolerable rate of muscle spasms, injection reactions or other adverse events.
Whether the effect held across sex, age and baseline body composition without being driven by a narrow subgroup.
What happened during the tirzepatide-withdrawal extension, particularly to appetite, weight regain and body composition.
Whether the combination offers enough benefit to justify another injectable biologic, extra monitoring and likely additional cost.
The Oria take
GYMINDA is materially different from another race for the largest weight-loss percentage. It asks whether a peptide-based incretin medicine can be paired with a muscle-biology drug to produce a better kind of loss. That is a clinically smarter endpoint, especially as GLP-1 and GIP therapies expand into older and more medically complex populations.
For now, the practical muscle-preservation tools remain less exotic: adequate protein for the individual, progressive resistance training when medically appropriate, attention to sleep and micronutrient sufficiency, and monitoring when weight is falling rapidly. An investigational antibody is not a substitute for those foundations, and it is not a do-it-yourself add-on to tirzepatide.
The scientific case is credible enough to watch closely. The direct clinical case for emugrobart plus tirzepatide is still unproven. Holding both ideas at once is the honest reading of the evidence.
Sources
Evidence Grade: C+ — A randomized phase 2 study provides strong proof-of-concept for combining an incretin therapy with a muscle-directed antibody, and tirzepatide body-composition data are peer reviewed. However, no efficacy results have been posted for emugrobart plus tirzepatide, so direct evidence for this exact combination remains pending.
Medical disclaimer: This article is for educational purposes only and is not medical advice. Emugrobart is investigational and is not approved for obesity or for preserving muscle during weight loss. Do not start, stop or combine prescription or research drugs based on this article. Discuss weight-loss treatment, nutrition, exercise and body-composition concerns with a qualified healthcare professional who knows your medical history.
Related Compounds
Build Your Personalised Protocol
Turn your research into a personalised supplementation protocol with the BioStack Generator.